SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Orchid Pharma informs about disclosure

04 Mar 2023 Evaluate
In continuation to earlier letter dated July 16, 2022 with respect to the approval granted to Orchid-Bio Pharma (wholly owned subsidiary) by Competent Authority under the Production Linked Incentive (PLI) Scheme for manufacturing of product ‘7 ACA’, Orchid Pharma has informed that the Company and Orchid Bio Pharma has entered into a Memorandum of Understanding (MoU) with an overseas technology provider for in-licensing 7ACA technology.

The above information is a part of company’s filings submitted to BSE.

Orchid Pharma Share Price

570.50 6.40 (1.13%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×